EN
Home/United States/Blog/Is Wegovy covered for heart protection or fatty liver (MASH) when weight loss isn’t?
USUnited States Coverage

Is Wegovy covered for heart protection or fatty liver (MASH) when weight loss isn’t?

Wegovy has three US approvals. Medicare, Medicaid and employer plans treat each one differently. Here is what the trials found and which road each use takes.

GLP Guidebook teamPublished Oct 12, 202610 min read15 sourcesWritten from published sources

Written for the United States. Other country versions are coming.

The short answer

Often, yes. Medicare can’t pay for weight-loss drugs, but its drug plans may cover Wegovy for heart-risk reduction or MASH. Medicaid must cover the heart use. In the SELECT trial, heart events fell from 8.0% to 6.5%; 16.6% stopped for side effects, against 8.2% on a dummy.

Key takeaways

  • Wegovy can be covered for heart risk or fatty liver even when a plan excludes weight loss, because US coverage rules follow the reason it is prescribed.5,6
  • The FDA approved Wegovy to cut heart-attack and stroke risk on March 8, 2024, and for MASH liver disease with F2 to F3 scarring on August 15, 2025.2,3
  • In SELECT, heart attack, stroke or heart death affected 6.5% on Wegovy against 8.0% on a dummy injection; 16.6% stopped Wegovy for side effects, against 8.2% on the dummy injection.8
  • Medicare’s GLP‑1 Bridge covers Wegovy only for weight, for a $50 monthly copay, and excludes people with MASH, who go through their Part D plan.10
  • Medicaid programs must cover Wegovy’s heart use, KFF says, while only 13 states covered GLP‑1s for obesity in January 2026.7
On this page
  1. What are Wegovy’s three approved uses in the US?
  2. Why does the reason for the prescription change who pays?
  3. What did the heart trial show?
  4. What did the fatty liver (MASH) trial show?
  5. How does Medicare handle each use?
  6. What about Medicaid and employer plans?
  7. What can you ask your prescriber and your plan?
  8. Questions people ask
  9. How we researched this

What are Wegovy’s three approved uses in the US?

The FDA has approved Wegovy injection for three jobs: lowering the risk of heart attack and stroke, long-term weight management, and a type of fatty liver disease called MASH.1

Before you go further
  • GLP‑1 medicines are prescription-only in the US. A licensed prescriber decides whether one fits you.
  • Label facts here come from the US prescribing information (the “label”), the official document the FDA approves for each medicine.1
  • This post explains coverage rules. It is not a plan for your treatment, and no use or brand guarantees any result.
  • Every risk of these medicines is in our side-effects guide.

Semaglutide is the medicine. Wegovy is one brand of it, made by Novo Nordisk. Ozempic is the same medicine under another brand, approved for type 2 diabetes.1,14 Think of acetaminophen: it is the medicine, and Tylenol is a brand name on the box.

  • Heart: to reduce the risk of heart death, heart attack or stroke in adults who already have heart or blood-vessel disease and obesity or overweight. The FDA approved this on March 8, 2024.1,2
  • Weight: to lose weight and keep it off in adults with obesity, adults with overweight plus a weight-related condition, and children 12 and older with obesity.1
  • Liver: to treat MASH with moderate to advanced scarring (stages F2 to F3), without cirrhosis, in adults. This came on August 15, 2025.1,3

MASH stands for metabolic dysfunction-associated steatohepatitis. It means fat in the liver plus inflammation and liver-cell damage. Its old name was NASH.1 The liver approval is an “accelerated approval”. That means the FDA approved it on early liver-biopsy results, and keeping the approval may depend on a longer trial.1,4

Why does the reason for the prescription change who pays?

Because US coverage rules treat weight loss differently from other uses. Medicare is barred by law from paying for drugs used for weight loss, but it can pay for the same drug used for something else.5

KFF, a health-policy research group, puts it this way: “Medicare has been prohibited by law from covering medications when used specifically for weight loss.”5 The heart approval changed that for one group. In 2024 Medicare told its drug plans that Wegovy now had a use “not specifically excluded from Medicare coverage”.6

Medicaid works in a similar way. States may leave weight-loss drugs out, but KFF says coverage is required for Wegovy’s heart use since March 2024.7

So the same pen can be covered or not, depending on why it is prescribed. That is why the use written on the prescription, and on any prior authorization (the form a plan asks your prescriber to fill in before it pays), matters.

What did the heart trial show?

In the SELECT trial, heart attack, stroke or heart death happened to 6.5% of people on Wegovy against 8.0% on a dummy injection, over about 3 years.8

How these trials work:

  • People are split at random into groups. One group gets a dummy injection (placebo) with no medicine in it.
  • Both groups keep their usual heart care and advice.
  • The gap between the groups is what the medicine added. An average is not a promise for any one person.
SELECTSemaglutide 2.4 mg (Wegovy) vs dummy injection

17,604 adults aged 45 or older, BMI 27 or more, with a past heart attack, stroke or blocked leg arteries, and no diabetes. Followed for about 40 months on average. Novo Nordisk paid for the trial.1,8

Had a heart attack, stroke or heart death

Wegovy6.5%
Dummy injection8.0%

About 15 fewer people in 1,000 had one of these events, by our arithmetic (80 minus 65 per 1,000).

Put the other way. Most people in both groups had none of these events. The harm side: 16.6% stopped Wegovy because of side effects, against 8.2% on the dummy injection.8 Heart death on its own was 2.5% against 3.0%, but the label says that difference was not proven.1

What did the fatty liver (MASH) trial show?

In the ESSENCE trial, liver inflammation cleared without more scarring in 63% of people on Wegovy against 34% on a dummy injection, judged by liver biopsy at 72 weeks.1,9

ESSENCESemaglutide 2.4 mg (Wegovy) vs dummy, MASH with F2–F3 scarring

800 adults with MASH confirmed by liver biopsy, analysed at 72 weeks. 56% had type 2 diabetes and 27% were Asian. Novo Nordisk paid for the trial.1,9

Share of people whose liver improved on biopsy

Inflammation cleared: Wegovy63%
Inflammation cleared: dummy34%
Less scarring: Wegovy37%
Less scarring: dummy22%

Average weight fell 10.5% on Wegovy, against 2.0% on the dummy injection.9 For someone at 210 lb (95 kg), 10.5% is about 22 lb (10 kg), by our arithmetic.

Two cautions from the label itself. First, the result is on the liver biopsy, not yet on liver failure or death; that is why the approval is “accelerated”.1 Novo Nordisk expects the longer part of the trial to report in 2029.3 Second, the label says there is “limited information in patients with MASH and a BMI <25”.1

RisksThe risks, in brief
  • Stomach effects are the most common. In the weight trials of Wegovy 2.4 mg, 44 in 100 felt sick (nausea) against 16 in 100 on the dummy injection.1
  • Pancreatitis (inflammation of the pancreas) has been seen with GLP‑1 medicines. The label says to stop if it is suspected.1
  • Gallstones were reported by 1.6% on Wegovy against 0.7% on the dummy injection in adult weight trials.1
  • Kidney injury can follow dehydration from vomiting or diarrhea.1
  • Thyroid tumors were seen in rodents. Wegovy carries a boxed warning and is not used with a personal or family history of medullary thyroid cancer or MEN 2, a rare inherited gland condition.1
Full detail in our side-effects guide →

How does Medicare handle each use?

Each use takes a different road. Weight goes through the temporary Medicare GLP‑1 Bridge; heart and liver uses go through your own Part D drug plan.10

Why it is prescribedWhich part of MedicareWhat to know
Weight managementMedicare GLP‑1 Bridge, July 1, 2026, to December 31, 202711$50 copay a month. Runs outside Part D. Needs one prior authorization per drug.10,11
Heart risk (established heart disease)Your Part D plan5,6Plans may cover it but are not required to. They may use prior authorization or step therapy.6
MASH (fatty liver with scarring)Your Part D plan10The Bridge excludes people with MASH; requests go to the Part D plan.10

The Bridge has its own clinical rules. At the start of treatment, the person must be 18 or older, be prescribed it for weight, and meet one of these:10

  • a BMI of 35 or more;
  • a BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or worse;
  • a BMI of 27 or more with prediabetes, a past heart attack, a past stroke, or symptomatic peripheral artery disease.

People with type 2 diabetes, moderate-to-severe sleep apnea or MASH can’t use the Bridge. Neither can anyone who already got a GLP‑1 through their Part D plan.10 Check at Medicare.gov/glp1bridge.11

A worked example. Someone with a past heart attack and a BMI of 28 could fit the Bridge’s weight rules and also Wegovy’s heart use. Which road applies depends on the use written on the prescription. Your prescriber and plan decide.

Free toolWhat would it cost you?

Works out a monthly and yearly cost from the prices you enter. No sign-up.

Coming soon

What about Medicaid and employer plans?

Medicaid must cover Wegovy’s heart use, while weight-loss coverage is a state choice. Employer plans set their own lists, so the answer depends on your plan’s formulary.7

As of January 2026, 13 state Medicaid programs covered GLP‑1s for obesity, down from 16 in October 2025.7 KFF lists required coverage for diabetes, the heart use and Zepbound’s sleep apnea use. We found no statement on the MASH use, so we don’t say either way.7

Without coverage, the cost is high. TrumpRx, a government price-listing site, shows Wegovy’s list price as $1,349 a month.12 Novo Nordisk’s own self-pay price is $349 a month for most pen doses, checked on October 12, 2026.13

One catch with paying cash. Novo Nordisk’s terms say that if you pay outside your insurance, the money “will not count toward your out-of-pocket limits or deductible”.13

What can you ask your prescriber and your plan?

Ask which approved use the prescription is for, and whether your plan covers that use. Those two answers decide most of the rest.

  1. The use. Is this for weight, for heart risk, or for MASH? Each has its own label criteria.1
  2. The plan’s rule. Does my plan cover Wegovy for this use, and does it need prior authorization?6
  3. The paperwork. What records does the prior authorization form ask for?
  4. Medicare only. Is this a Bridge request or a Part D request? The prescriber writes “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” only for the weight route.10
Get help now: call 911 if someone collapses, has a seizure, has trouble breathing or can’t be woken.15 For severe stomach pain that won’t go away, sometimes spreading to the back, stop the medicine and call your prescriber right away; the label names this as a pancreatitis sign.1 Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, needs medical help straight away.1 Poison Control is 1-800-222-1222.15

Questions people ask

Does Medicare cover Wegovy for heart disease?

Part D plans may cover it for its heart use, since that use is not excluded by law, but they are not required to, and may need prior authorization.6

Does Medicare cover Wegovy for fatty liver (MASH)?

MASH requests go to your Part D plan. The Medicare GLP‑1 Bridge excludes people with MASH.10

Is Wegovy covered for weight loss by Medicare?

Only through the temporary Medicare GLP‑1 Bridge, from July 1, 2026, to December 31, 2027, for a $50 monthly copay if you meet its rules.10,11

Does Medicaid cover Wegovy for heart protection?

KFF says Medicaid coverage has been required for Wegovy’s heart use since March 2024. Coverage for weight loss is up to each state.7

How much did Wegovy lower heart risk?

In SELECT, 6.5% on Wegovy had a heart attack, stroke or heart death over about 3 years, against 8.0% on a dummy injection.8

How we researched this

On October 12, 2026, we read the current US Wegovy label, the FDA’s 2024 heart approval, the FDA’s 2025 MASH approval letter and Novo Nordisk’s announcement. We read the SELECT and ESSENCE abstracts, CMS’s Bridge prescriber sheet, and three KFF briefs on Medicare and Medicaid.

Both trials were paid for by Novo Nordisk, which makes Wegovy. Prices are the list price shown on TrumpRx and the maker’s published self-pay price, both checked on October 12, 2026. We left out savings-card and discount prices, and we name no pharmacy, clinic or telehealth service.

Before you move on

  • Coverage follows the use on the prescription: weight, heart risk or MASH.
  • Medicare pays for weight only through the temporary Bridge; heart and MASH go to Part D.
  • SELECT: 6.5% on Wegovy had a heart event, against 8.0% on a dummy injection; 16.6% stopped Wegovy for side effects, against 8.2% on the dummy.
  • The MASH approval rests on biopsy results; a longer trial is still running.
Side effects and risksShould I consider it?Cost calculator

More from the US blog

USUnited StatesDoes Medicare cover Wegovy or Zepbound? The GLP-1 Bridge USUnited StatesMedicaid and GLP-1s: which states cover them USUnited StatesZepbound for sleep apnea: who qualifies
About GLP Guidebook

The monthly US update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: FDA approvals and safety notices, label changes, Medicare and Medicaid coverage changes, and published price changes. How we write

Was this post easy to understand?

Sources

  1. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information and Medication Guide, revised 06/2026. novo-pi.com
  2. U.S. Food and Drug Administration (FDA). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. Press release, March 8, 2024. fda.gov
  3. Novo Nordisk. Wegovy approved in the US for the treatment of MASH. Company announcement, August 15, 2025. novonordisk.com
  4. FDA. NDA 215256/S-024 accelerated approval letter to Novo Nordisk (Wegovy, MASH indication). 2025. accessdata.fda.gov
  5. KFF. What to know about the BALANCE Model for GLP‑1s in Medicare and Medicaid and the Medicare GLP‑1 Bridge. Updated May 11, 2026. kff.org
  6. KFF. A new use for Wegovy opens the door to Medicare coverage for millions of people with obesity. April 24, 2024. kff.org
  7. KFF. Medicaid coverage of and spending on GLP‑1s. January 16, 2026. kff.org
  8. Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–32. Funded by Novo Nordisk. DOI · PMID 37952131
  9. Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025;392:2089–99. Funded by Novo Nordisk. DOI · PMID 40305708
  10. Centers for Medicare & Medicaid Services (CMS). Medicare GLP‑1 Bridge: information for prescribers. CMS Product No. 12235, June 2026. cms.gov
  11. CMS. Medicare GLP‑1 Bridge. Page last modified July 13, 2026. cms.gov
  12. TrumpRx.gov (US government price-listing site). GLP‑1 listings with "original price", opened October 12, 2026. trumprx.gov
  13. Novo Nordisk. Wegovy cost, coverage and savings resources (self-pay prices). NovoCare, opened October 12, 2026. novocare.com
  14. Novo Nordisk. Ozempic (semaglutide) injection: US prescribing information, revised 05/2026. novo-pi.com
  15. Poison Control (National Capital Poison Center). Opened October 12, 2026. poison.org

Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical, legal or tax advice. Talk to a qualified doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write